| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director, 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | /s/ Noubar B. Afeyan, Ph.D. | 02 Mar 2026 | 0001222012 |
| Flagship VentureLabs VI LLC | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | Flagship VentureLabs VI LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of Manager | 02 Mar 2026 | 0001725008 |
| Flagship Pioneering Fund VI, L.P. | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | Flagship Pioneering Fund VI, L.P., By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner | 02 Mar 2026 | 0001716926 |
| Flagship Pioneering Fund VII, L.P. | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | Flagship Pioneering Fund VII, L.P., By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner | 02 Mar 2026 | 0001805916 |
| Nutritional Health LTP Fund, L.P. | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | Nutritional Health LTP Fund, L.P., By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner | 02 Mar 2026 | 0001780956 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | Flagship Pioneering Special Opportunities Fund II, L.P., By: /s/ Noubar B. Afeyan Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner | 02 Mar 2026 | 0001761283 |
| FPN II, L.P. | 10%+ Owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE | FPN II, L.P., By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager of General Partner | 02 Mar 2026 | 0001918834 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GENB | Common Stock | Conversion of derivative security | +12,723,940 | 12,723,940 | 02 Mar 2026 | By Flagship Pioneering Fund VI, L.P. | F1, F2 | |||
| transaction | GENB | Common Stock | Conversion of derivative security | +13,702,224 | 13,702,224 | 02 Mar 2026 | By Flagship Pioneering Fund VII, L.P. | F1, F3 | |||
| transaction | GENB | Common Stock | Conversion of derivative security | +987,491 | 987,491 | 02 Mar 2026 | By Nutritional Health LTP Fund, L.P. | F1, F4 | |||
| transaction | GENB | Common Stock | Conversion of derivative security | +2,777,752 | 2,777,752 | 02 Mar 2026 | By Flagship Pioneering Special Opportunities Fund II, L.P. | F1, F5 | |||
| transaction | GENB | Common Stock | Conversion of derivative security | +2,777,752 | 2,777,752 | 02 Mar 2026 | By FPN II, L.P. | F1, F6 | |||
| transaction | GENB | Common Stock | Purchase | $25,000,000 | +1,562,500 | +11% | $16.00 | 15,264,724 | 02 Mar 2026 | By Flagship Pioneering Fund VII, L.P. | F3 |
| transaction | GENB | Common Stock | Purchase | $25,000,000 | +1,562,500 | +56% | $16.00 | 4,340,252 | 02 Mar 2026 | By FPN II, L.P. | F6 |
| transaction | GENB | Common Stock | Purchase | $25,000,000 | +1,562,500 | $16.00 | 1,562,500 | 02 Mar 2026 | By Pioneering Medicines 02, LLC | F7 | |
| holding | GENB | Common Stock | 25,016,458 | 26 Feb 2026 | By Flagship VentureLabs VI, LLC | F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GENB | Stock Option (Right to Buy) | Award | $0 | +29,561 | $0.000000 | 29,561 | 26 Feb 2026 | Common Stock | 29,561 | $16.00 | Direct | F9 | |
| transaction | GENB | Series A Preferred Stock | Conversion of derivative security | $0 | -18,483,785 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 12,168,390 | By Flagship Pioneering Fund VI, L.P. | F1, F2 | |
| transaction | GENB | Series A Preferred Stock | Conversion of derivative security | $0 | -17,016,215 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 11,202,248 | By Flagship Pioneering Fund VII, L.P. | F1, F3 | |
| transaction | GENB | Series A Preferred Stock | Conversion of derivative security | $0 | -1,500,000 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 987,491 | By Nutritional Health LTP Fund, L.P. | F1, F4 | |
| transaction | GENB | Series B Preferred Stock | Conversion of derivative security | $0 | -843,881 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 555,550 | By Flagship Pioneering Fund VI, L.P. | F1, F2 | |
| transaction | GENB | Series B Preferred Stock | Conversion of derivative security | $0 | -1,265,822 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 833,325 | By Flagship Pioneering Fund VII, L.P. | F1, F3 | |
| transaction | GENB | Series B Preferred Stock | Conversion of derivative security | $0 | -2,953,586 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 1,944,427 | By Flagship Pioneering Special Opportunities Fund II, L.P. | F1, F5 | |
| transaction | GENB | Series B Preferred Stock | Conversion of derivative security | $0 | -2,109,704 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 1,388,876 | By FPN II, L.P. | F1, F6 | |
| transaction | GENB | Series C Preferred Stock | Conversion of derivative security | $0 | -2,531,644 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 1,666,651 | By Flagship Pioneering Fund VII, L.P. | F1, F3 | |
| transaction | GENB | Series C Preferred Stock | Conversion of derivative security | $0 | -1,265,822 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 833,325 | By Flagship Pioneering Special Opportunities Fund II, L.P. | F1, F5 | |
| transaction | GENB | Series C Preferred Stock | Conversion of derivative security | $0 | -2,109,704 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 1,388,876 | By FPN II, L.P. | F1, F6 |
| Id | Content |
|---|---|
| F1 | Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F2 | Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| F3 | Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F4 | Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F5 | Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F6 | Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F7 | Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F8 | Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| F9 | The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
Form 1 of 2: This is the first of two Forms 4 being filed relating to the same event. The Form 4 is being split into two filings because there are more than 10 Reporting Persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 Reporting Persons. Each Form 4 is filed by Designated Filer Noubar Afeyan.